Immune stimulation in sepsis: To be or not to be?

Chest

Volumn 127, Issue 6, 2005, Pages 1882-1885

  Napolitano, Lena M ^a,b  

^a University of Maryland School of Medicine ^*

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

BACTERIAL INFECTION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; EDITORIAL; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOSTIMULATION; INFECTION PREVENTION; INNATE IMMUNITY; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; TREATMENT RESPONSE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HOSPITALIZATION; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METHODOLOGY; NEWBORN; NOTE; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INFANT, NEWBORN; MALE; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEPSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 21844446629     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.6.1882     Document Type: Editorial

References (19)

1. Barreda DR, Hanington PC, Belosevic M. Regulation of myeloid development and function by colony stimulating factors. Dev Comp Immunol 2004; 28:509-554
2. Liles WC. Immunomodulatory approaches to augment phagocyte-mediated host defense for treatment of infectious diseases. Semin Respir Infect 2001; 16:11-17
3. Komrokji RS, Lyman GH. The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opin Biol Ther 2004; 4:1897-1910
4. Sung L, Nathan PC, Lange B, et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22:3350-3356
5. Bohlius J, Reiser M, Schwarzer G, et al. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 2003; 122:413-423
6. Bohlius J, Reiser M, Schwarzer G, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev (data-base online). Issue 1, 2004
7. Held TK, Cross AS. Role of hematopoietic growth factors in non-neutropenic infections and sepsis. Curr Opin Hematol 1999; 6:176-183
8. Hubel K, Dale DC, Liles WC. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis 2002; 185:1490-1501
9. Carr R, Modi N, Dore C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev (database online). Issue 3, 2003
10. Root RK, Dale DC. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis 1999; 179(suppl):S342-S352
11. Presneill JJ, Waring PM, Layton JE, et al. Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: relation to disease severity, multiple organ dysfunction, and mortality. Crit Care Med 2000; 28:2344-2354
12. Perry SE, Mostafa SM, Wenstone R, et al. Low plasma granulocyte- macrophage colony stimulating factor is an indicator of poor prognosis in sepsis. Intensive Care Med 2002; 28:981-984
13. Mellstedt H, Fagerberg J, Frodin JE, et al. Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Curr Opin Hematol 1999; 6:169-175
14. Karzai W, von Specht BU, Parent C, et al. G-CSF during Escherichia coll versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 1999; 159(suppl):1377-1382
15. Sevransky JE, Parent C, Cui X, et al. Granulocyte colony-stimulating factor has differing effects comparing intravascular versus extravascular models of sepsis. J Trauma 2004; 57:618-625
16. Azoulay E, Delclaux C. Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients? Intensive Care Med 2004; 30:10-17
17. Calhoun DA, Lunoe M, Du Y, et al. Granulocyte colony-stimulating factor serum and urine concentrations in neutropenic neonates before and after intravenous administration of recombinant granulocyte colony-stimulating factor. Pediatrics 2000; 105:392-397
18. Rafatpanah H, Bennett E, Pravica V, et al. Association between novel GM-CSF gene polymorphisms and the frequency and severity of atopic dermatitis. J Allergy Clin Immunol 2003; 112:593-598
19. Aggarwal A, Baker CS, Evans TW, et al. G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome. Eur Respir J 2000; 15:895-901